Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Low Dose Metronomic Cyclophosphamide and Methotrexate Chemotherapy in Combination With Aspirin in Patients With Stage II-III Breast Cancer Who Fail to Achieve a Pathologic Complete Response After Neoadjuvant Chemotherapy

NCT01612247 is registered in ClinicalTrials.gov with University of Vermont as lead sponsor.

NCT NCT01612247
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01612247 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Low Dose Metronomic Cyclophosphamide and Methotrexate Chemotherapy in Combination With Aspirin in Patients With Stage II-III Breast Cancer Who Fail to Achieve a Pathologic Complete Response After Neoadjuvant Chemotherapy
Lead sponsor
University of Vermont
Phase
Not applicable
Overall status
Unknown status
Start date
February 28, 2011
Completion date
February 28, 2014
Enrollment
13 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer